Methylprednisolone Acetate Injection shortage
Methylprednisolone Acetate Injection is currently listed in shortage by the FDA. The FDA lists 23 affected products. The reported reason: Other; Demand increase for the drug; Shortage of an active ingredient. This page was last refreshed from FDA data on Sep 25, 2026.
Methylprednisolone acetate injection has been in shortage for over a year, driven by manufacturing delays, ingredient shortages, and rising demand. Some strengths remain available from other makers, including Depo-Medrol and generic versions at 40 mg/mL and 80 mg/mL.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Methylprednisolone Acetate Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 21, 2026Currently in shortage23 of 23 products affected.
-
Sep 18, 2026FDA refreshed this shortage record3 products updated.
-
Sep 17, 2026FDA refreshed this shortage record3 products updated.
-
Jun 17, 2026FDA refreshed this shortage record4 products updated.
-
Jun 16, 2022More presentations reported1 more product added to the shortage.
-
Dec 15, 2021First reported to the FDA22 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Amneal Pharmaceuticals 📞 866-525-7270 4 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5) | — | Available | — | — |
| Current | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5) | — | Available | — | — |
| Current | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1) | — | Available | — | — |
| Current | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1) | — | Limited Availability | On backorder. Estimated recovery: late July | Other |
Manufacturer: Eugia US LLC 📞 888-238-7880 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01) | — | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug |
| Current | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01) | — | Unavailable | On backorder. Recovery: TBD. Check wholesalers for inventory | Demand increase for the drug |
Manufacturer: Par Health, USA LLC 📞 800-828-9393 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01) | — | Unavailable | Estimated recovery: TBD | Other |
Manufacturer: Pfizer Inc. 📞 844-646-4398 13 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03) | — | Limited Availability | Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01) | — | Limited Availability | Limited Supply Available. Next Delivery and Estimated Recovery: December 2026 | Demand increase for the drug |
| Current | Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01) | — | Available | — | — |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03) | — | Limited Availability | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01) | — | Limited Availability | Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026 | Demand increase for the drug |
| Current | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12) | — | Available | — | — |
| Current | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03) | — | Limited Availability | Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23) | — | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02) | — | Available | — | — |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22) | — | Unavailable | Next Delivery: October 2026; Estimated Recovery: December 2026 | Demand increase for the drug |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02) | — | Available | — | — |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51) | — | Available | — | — |
| Current | Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52) | — | Available | — | — |
Manufacturer: Sagent Pharmaceuticals 📞 866-625-1618 3 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10) | — | Unavailable | Estimated recovery: November 2026, | Shortage of an active ingredient |
| Current | Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05) | — | Limited Availability | Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry | Shortage of an active ingredient |
| Current | Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05) | — | Unavailable | Estimated recovery: November 2026 | Shortage of an active ingredient |
These rows are manufacturer reports to the FDA for Methylprednisolone Acetate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Methylprednisolone Acetate Injection? options further down this page.
Why is Methylprednisolone Acetate Injection in shortage?
There are actually a few things driving this shortage, depending on the manufacturer. Pfizer (which makes the brand-name Depo-Medrol) is dealing with a combination of a production hold-up at the factory and more people needing the medication than usual. Several of their specific package sizes — including certain 40 mg/mL and 80 mg/mL vials — are in limited supply, with next deliveries expected as early as September 2026 and full recovery estimated anywhere from December 2026 to March 2027, depending on the package. Notably, Pfizer's 20 mg/mL, one 40 mg/mL package, and one 80 mg/mL package are currently listed as available. Sagent Pharmaceuticals is facing a shortage of the active ingredient itself, leaving their 40 mg/mL vials completely unavailable and their 80 mg/mL vials very limited, with recovery estimated for November 2026. Eugia is fully out of both their 40 mg/mL and 80 mg/mL sizes due to higher-than-usual demand, with no firm recovery date yet. Amneal has most of their sizes available, though one 40 mg/mL package is on backorder with a recovery estimated for late July. Par Health's 80 mg/mL has no recovery date set.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Methylprednisolone Acetate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Methylprednisolone Acetate Injection?
Methylprednisolone acetate injection is currently on the FDA shortage list, and I want you to know right away that every strength still has an available source, so this is a manageable situation.
All three strengths — 20 mg/1 mL, 40 mg/1 mL, and 80 mg/1 mL — still have supply from at least one manufacturer. None of the strengths are completely without a source right now. Some individual products from certain makers are on backorder or limited, but others are marked as available. For example, one manufacturer reports the 40 mg, 80 mg, and 20 mg all available, while others show limited supply or restocking dates ranging into late 2026 and early 2027.
The FDA lists the reasons as increased demand, a shortage of an active ingredient, and other manufacturing factors. Three of five manufacturers on this record still report supply, and this has been an ongoing situation for over a year.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to order your strength — they can check wholesalers and other manufacturers, since some makers still have stock.
- The same medicine is made by other companies (such as Sandoz, Amneal, Endo, and others); your pharmacy may be able to source one, though it may not be in local stock.
- If your exact product can't be found, ask your prescriber or pharmacist about clinician-chosen options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national data and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Methylprednisolone Acetate Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Methylprednisolone Acetate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Depo-Medrol | METHYLPREDNISOLONE ACETATE 80 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Pharmacia & Upjohn Company LLC | 00009-3475-22 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 80 mg/mL | Injection, Suspension · Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Sandoz Inc. | 00781-3516-75 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 40 mg/mL | Injection, Suspension · Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Sandoz Inc. | 00781-3522-70 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 40 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Endo USA, Inc. | 42023-0239-01 |
| Depo-Medrol | METHYLPREDNISOLONE ACETATE 80 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | A-S Medication Solutions | 50090-0436-00 |
| Depo-Medrol | METHYLPREDNISOLONE ACETATE 40 mg/mL | Injection, Suspension · Intralesional, Intramuscular, Intrasynovial, Soft Tissue | A-S Medication Solutions | 50090-0556-00 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 40 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Eugia US LLC | 55150-0313-25 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 80 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Eugia US LLC | 55150-0314-25 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 40 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Amneal Pharmaceuticals NY LLC | 60219-1573-01 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 80 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Amneal Pharmaceuticals NY LLC | 60219-1574-01 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 80 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Soft Tissue | Amneal Pharmaceuticals LLC | 70121-1552-01 |
| Methylprednisolone Acetate | METHYLPREDNISOLONE ACETATE 40 mg/mL | Injection, Suspension · Intra-Articular, Intralesional, Intramuscular, Intrasynovial, Soft Tissue | Amneal Pharmaceuticals LLC | 70121-1609-01 |
Therapeutic equivalents & pricing 20 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Methylprednisolone acetate 40 mg/mL | Amneal | 1 vial | $5.808 | AB | Availability likely |
| Depo-Medrol 40 mg/mL | Pharmacia | 1 vial | $6.827 | — | Availability likely |
| Methylprednisolone acetate 40 mg/mL | Amneal | 1 vial | $7.490 | AB | Availability likely |
| Methylprednisolone acetate 80 mg/mL | Amneal | 1 vial | $11.924 | AB | Availability likely |
| Methylprednisolone acetate 80 mg/mL | Amneal | 1 vial | $11.924 | AB | Availability likely |
| Methylprednisolone acetate 80 mg/mL | Amneal | 1 vial | $11.924 | AB | Availability likely |
| Depo-Medrol 80 mg/mL | Pharmacia | 1 vial | $18.317 | — | Discontinued |
| Depo-Medrol 40 mg/mL | A-S | 1 vial | — | — | FDA listed |
| Methylprednisolone acetate 40 mg/mL | A-S | 1 vial | — | AB | FDA listed |
| Methylprednisolone Acetate 40 mg/mL | Caplin | 25 vials | — | AB | FDA listed |
| Methylprednisolone acetate 40 mg/mL | Amneal | 25 vials | — | AB | FDA listed |
| Methylprednisolone acetate 40 mg/mL | Sportpharm | 1 vial | — | AB | FDA listed |
| methylprednisolone acetate 40 mg/mL | Sagent | 1 vial | — | AB | FDA listed |
| methylprednisolone acetate 40 mg/mL | Sportpharm | 1 vial | — | AB | FDA listed |
| Depo-Medrol 80 mg/mL | A-S | 1 vial | — | — | FDA listed |
| Methylprednisolone acetate 80 mg/mL | A-S | 25 vials | — | AB | FDA listed |
| Methylprednisolone Acetate 80 mg/mL | Caplin | 25 vials | — | AB | FDA listed |
| Methylprednisolone acetate 80 mg/mL | Amneal | 25 vials | — | AB | FDA listed |
| Depo-Medrol 80 mg/mL | Asclemed | 1 ml | — | — | FDA listed |
| Methylprednisolone Acetate 80 mg/mL | Eugia | 1 vial | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Methylprednisolone Acetate Injection — that fall in the same broad treatment class (glucocorticoids) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other rheumatology shortages
Methylprednisolone Acetate Injection shortage FAQs
Is Methylprednisolone Acetate Injection in shortage?
Why is Methylprednisolone Acetate Injection in shortage?
Which products are affected?
When will Methylprednisolone Acetate Injection be available again?
Can I still get Methylprednisolone Acetate somewhere?
What should I do if I take Methylprednisolone Acetate Injection?
Still have a question about the Methylprednisolone Acetate Injection shortage?
Ask a pharmacist about this shortage →View Methylprednisolone Acetate Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.